Novo Nordisk is investing in the Boston area, with an exciting plan to expand its research and development operations and create over 200 new jobs in 2021. This is an exciting move for the company, and a great opportunity for the local community. With the extra jobs, Novo Nordisk is helping to provide a much-needed boost to the local economy.
In a move to expand its research and development capabilities, the Danish drugmaker is migrating most of its U.S.-based research work to a new R&D hub. This move is set to bolster activities and staffing in other locations, providing exciting opportunities for the drugmaker’s growth and success.
Novo is streamlining operations by cutting 80 jobs in Seattle and 20 in Indianapolis. Employees affected by the move will be given the chance to apply for other positions at different sites.
Novo’s Seattle site will remain an active hub of digital therapy, data science, and artificial therapy. Additionally, the company will continue its cutting-edge stem cell work in Fremont, California, ensuring that it remains a leader in the field.
Novo is set to make Boston its “principal R&D location in the U.S.” with a major expansion of its research and development hub. The Danish company’s new facility will be one of its largest outside of Denmark and will solidify Boston as a hub for innovative developments.
Novo has announced the creation of 200 new roles in the Boston area, with over 150 of them being lab-based and focused on clinical development in data science, biology, chemistry research, and RNA interference. These positions will be based in Novo’s existing Lexington, Cambridge, and Watertown, Massachusetts sites, offering a wide variety of opportunities to join the expanding Novo team.
Novo Nordisk, a leading biopharmaceutical company, is taking their research capabilities to the next level with their expansion into Boston. With over 1,000 life science companies and top institutions in the city, Novo Nordisk has the opportunity to tap into an array of innovative technologies and develop treatments for chronic conditions. According to Chief Scientific Officer, Marcus Schindler, Ph.D., this expansion will help Novo Nordisk advance their pipeline into new modalities, ultimately creating better outcomes for patients.
Novo has made a bold move in their pursuit of innovation, announcing plans to transform a 100,000-square-foot space in Lexington into a revolutionary lab facility. This lab will serve as the hub for their RNA interference research and oral formulation projects, set to launch in 2022. With this significant investment, Novo is sure to make waves in the biotech sector.
In November 2021, Novo cemented its position in the RNA interference space with its $3.3 billion purchase of partner Dicerna Pharmaceuticals. This move gives Novo access to Dicerna’s groundbreaking platform, allowing its candidates to reach targets inside cells, particularly in hepatic and extrahepatic tissues.
Dicerna, a groundbreaking biotech company based in Lexington, Massachusetts, is revolutionizing the world of biotechnology with its cutting-edge research and innovative products. From developing groundbreaking treatments to uncovering new insights in the field, the company is paving the way for a brighter future in the biotechnology industry.
Other Expansions in the Industry
Amid the struggles of the industry, rare glimmers of hope can be found in the announcements of companies like Novo, who are still determined to expand. There are other companies too that have held fast to their plans for growth in the midst of the downturn.
AstraZeneca is making a major investment in Toronto’s scientific and high-tech community, with 500 new jobs to be created in a newly-established Rare Disease Development Hub. The hub will focus on research into rare diseases, and is expected to drive innovation and progress in this area. This is a significant move for AstraZeneca, which is making a commitment to advancing its R&D operations in Toronto.
In June 2022, Regeneron broke ground on its ambitious $1.8-billion expansion in Tarrytown, New York, with plans to add at least 1,000 new full-time roles. This state-of-the-art facility will transform the area and is expected to be completed by 2027. It’s an exciting time for the local community and Regeneron alike, as the new facility promises to bring innovative technologies and a wealth of job opportunities.
Eli Lilly recently made a major investment in its home state of Indiana, plunking down a whopping $2.1 billion to construct two new manufacturing facilities. This move is set to bring an estimated 500 new jobs to the state, while significantly increasing Lilly’s capacity to produce active ingredients and genetic medicines. With this substantial investment, Lilly is demonstrating its commitment to the Hoosier State and its future.